Stopping lopinavir/ritonavir in COVID-19 patients: duration of the drug interacting effect

Stader, F.; Khoo, S.; Stoeckle, M.; Back, D.; Hirsch, H. H.; Battegay, M.; Marzolini, C.

doi:10.1093/jac/dkaa253

Stopping lopinavir/ritonavir in COVID-19 patients: duration of the drug interacting effect

Details

Download: Stader.pdf (134.24 [Ko])
State: Public
Version: Final published version
License: Not specified

Serval ID

serval:BIB_43B047B70CB0

Type

Article: article from journal or magazin.

Collection

Publications

Institution

UNIL/CHUV

Title

Stopping lopinavir/ritonavir in COVID-19 patients: duration of the drug interacting effect

Journal

J Antimicrob Chemother

Author(s)

Stader F., Khoo S., Stoeckle M., Back D., Hirsch H. H., Battegay M., Marzolini C.

ISSN

1460-2091 (Electronic)
0305-7453 (Print)

ISSN-L

0305-7453

Publication state

Published

Issued date

2020

Peer-reviewed

Oui

Volume

75

Number

10

Pages

3084-3086

Language

english

Notes

Stader, Felix
Khoo, Saye
Stoeckle, Marcel
Back, David
Hirsch, Hans H
Battegay, Manuel
Marzolini, Catia
eng
SNSF_/Swiss National Science Foundation/Switzerland
Letter
Research Support, Non-U.S. Gov't
England
J Antimicrob Chemother. 2020 Oct 1;75(10):3084-3086. doi: 10.1093/jac/dkaa253.

Keywords

Adult, Aged, Aged, 80 and over, *Betacoronavirus, Covid-19, Coronavirus Infections/drug therapy/*metabolism, Cytochrome P-450 CYP3A Inhibitors/administration & dosage/*metabolism, Drug Interactions/*physiology, Drug Therapy, Combination, Female, Humans, Lopinavir/administration & dosage/*metabolism, Male, Middle Aged, Pandemics, Pneumonia, Viral/drug therapy/*metabolism, Ritonavir/administration & dosage/*metabolism, SARS-CoV-2, Time Factors, Withholding Treatment/trends, Young Adult

URN

urn:nbn:ch:serval-BIB_43B047B70CB05

OAI-PMH

oai:serval.unil.ch:BIB_43B047B70CB0

DOI

10.1093/jac/dkaa253

Pubmed

32556272

Funding(s)

Swiss National Science Foundation / 188504

Create date

25/08/2023 6:17